Company Overview and News

 
Japara Healthcare Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-02-26 seekingalpha
The following slide deck was published by Japara Healthcare Ltd. ADR in conjunction with their 2018 Q2 earnings call.

 
Telstra feeling the pressure of NBN rollout

2018-01-22 perthnow.com.au
TELSTRA may need to cut costs more aggressively as revenue comes under pressure amid the rollout of the National Broadband Network and intense competition, Australia’s biggest listed investment company says.

 
US tax joy, commodity lift kicks off ASX Santa rally

2017-12-19 theage.com.au
Investors flooded into shares on Tuesday, buoyed by new record highs on Wall Street and a broad-based lift in commodity prices. 

 
US tax joy, commodity lift kicks off ASX Santa rally

2017-12-19 smh.com.au
Investors flooded into shares on Tuesday, buoyed by new record highs on Wall Street and a broad-based lift in commodity prices. 

 
Wage fraud claims dunk Retail Food Group to bottom of ASX 200

2017-12-18 theage.com.au
Allegations of widespread wage fraud have sunk troubled franchising giant Retail Food Group to the bottom of the S&P ASX 200, putting it at risk of being dropped from the benchmark index.

 
Wage fraud claims dunk Retail Food Group to bottom of ASX 200

2017-12-18 smh.com.au
Allegations of widespread wage fraud have sunk troubled franchising giant Retail Food Group to the bottom of the S&P ASX 200, putting it at risk of being dropped from the benchmark index.

 
Japara Healthcare (JRHHY) Presents At UBS Australasia Conference 2017 - Slideshow

2017-11-14 seekingalpha
The following slide deck was published by Japara Healthcare Ltd. ADR in conjunction with this event.

 
ASX in holding pattern as banks slip

2017-10-24 theage.com.au
The Australian sharemarket consolidated around the five-and-half-month high it hit late last week as a two-week run of gains runs out of puff.

 
ASX in holding pattern as banks slip

2017-10-24 smh.com.au
The Australian sharemarket consolidated around the five-and-half-month high it hit late last week as a two-week run of gains runs out of puff.

 
ASX posts fall for the first time in three sessions on soft miners

2017-10-10 theage.com.au
Australian shares fell for the first time in three sessions, dragged lower by the big miners.

 
ASX posts fall for the first time in three sessions on soft miners

2017-10-10 smh.com.au
Australian shares fell for the first time in three sessions, dragged lower by the big miners.

 
Harvey Norman hit hard as ASX edges lower

2017-03-20 theage.com.au
The S&P/ASX200 index remains unable to maintain gains above the 5800 level, with broad-based losses across most sectors erasing last week's positive moment.

 
Harvey Norman hit hard as ASX edges lower

2017-03-20 smh.com.au
The S&P/ASX200 index remains unable to maintain gains above the 5800 level, with broad-based losses across most sectors erasing last week's positive moment.

 
Miners lead ASX rebound

2016-12-06 theage.com.au
Shares rebounded on Tuesday, with industrials and miners leading the charge, while the Australian dollar shrugged off expectations of slowing growth.

 
Miners lead ASX rebound

2016-12-06 smh.com.au
Shares rebounded on Tuesday, with industrials and miners leading the charge, while the Australian dollar shrugged off expectations of slowing growth.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...